Evidence map›Paper›PMID 35659243›Full record

ArticleJournal of nanobiotechnology2022

Abplatin

Xing Li, Lingpu Zhang, Tuo Li, Shumu Li, Wenjing Wu, Lingyu Zhao, Peng Xie, Jinqi Yang, Peipei Li, Yangyang Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xing LiBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Lingpu ZhangBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Tuo LiBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Shumu LiBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Wenjing WuBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Lingyu ZhaoBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Peng XieDepartment of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
Jinqi YangBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Peipei LiGraduate School, University of Chinese Academy of Sciences, Beijing, 100049, China.
Yangyang ZhangBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China.
Haihua XiaoGraduate School, University of Chinese Academy of Sciences, Beijing, 100049, China.
Yingjie YuCollege of Life Science and Technology; State Key Laboratory of Organic-Inorganic Composites, Beijing University of Chemical Technology, Beijing, 100029, China. yuyingjie@mail.buct.edu.cn.
Zhenwen ZhaoBeijing National Laboratory for Molecular Sciences, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry Chinese Academy of Sciences, Beijing Mass Spectrum Center, Beijing, 100190, China. zhenwenzhao@iccas.ac.cn.

Funding

National Natural Science Foundation of China 21635008National Natural Science Foundation of China 21874142the National Key R&D Program of China 2018YFA0800900
6 · The paper itself

Abstract

backgroundCisplatin, the alkylating agent of platinum(II) (Pt(II)), is the most common antitumor drug in clinic; however, it has many side effects, therefore it is higly desired to develop low toxicity platinum(IV) (Pt(IV)) drugs. Multi-omics analysis, as a powerful tool, has been frequently employed for the mechanism study of a certain therapy at the molecular level, which might be helpful for elucidating the mechanism of platinum drugs and facilitating their clinical application.

methodsStrating form cisplatin, a hydrophobic Pt(IV) prodrug (CisPt(IV)) with two hydrophobic aliphatic chains was synthesized, and further encapsulated with a drug carrier, human serum albumin (HSA), to form nanoparticles, namely AbPlatin

resultsCompared with cisplatin, Abplatin

conclusionsThis research highlighted the development of Abplatin

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsProdrugsCell Line, TumorCisplatinHumansPlatinumAntineoplastic AgentsCisplatinPlatinumProdrugsAbplatin(IV)CisplatinMulti-omicsNanoparticlesPt(IV) drugs

Identifiers

PMID35659243
PMCPMC9164404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.